Loading...
Please wait, while we are loading the content...
Aryloxazolidinone Antibiotic Compounds
| Content Provider | The Lens |
|---|---|
| Abstract | wherein Y represents hydrogen or certain chemical groups. These compounds are useful antimicrobial agents effective against a variety of pathogens including inter alia Gram-negative aerobic and anaerobic bacteria. |
| Related Links | https://www.lens.org/lens/patent/012-153-799-724-336/frontpage |
| Language | English |
| Publisher Date | 2019-12-05 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Patent |
| Jurisdiction | United States of America |
| Date Applied | 2018-02-16 |
| Applicant | Idorsia Pharmaceuticals Ltd |
| Application No. | 201816486794 |
| Claim | A compound of formula I wherein Y represents hydrogen or a group selected from Y 1 or Y 2 or a salt thereof. The compound according to claim 1 which is (S)-1-{3-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propylamino}-1,2-dihydro-pyrrolo[3,2,1-ij]quinolin-4-one or a pharmaceutically acceptable salt thereof. The compound according to claim 1 which is ((S)-4-oxo-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-{3-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-carbamic acid phosphonooxymethyl ester or a pharmaceutically acceptable salt thereof. The compound according to claim 1 which is 3-(2-phosphonooxy-phenyl)-propionic acid(((S)-4-oxo-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-{3-M-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-carbamoyloxy)-methyl ester or a pharmaceutically acceptable salt thereof. A composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, further comprising at least one pharmaceutically acceptable excipient. A medicament comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof. A method for treatment of a bacterial infection comprising administering the compound of claim 1 , or a pharmaceutically acceptable salt thereof. A method for treatment of a bacterial infection mediated by Gram-negative bacteria comprising administering the compound of claim 1 , or a pharmaceutically acceptable salt thereof. A method for treatment of a bacterial infection mediated by bacteria selected from the group comprising Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa comprising administering the compound of claim 1 , or a pharmaceutically acceptable salt thereof. |
| CPC Classification | Specific Therapeutic Activity Of Chemical Compounds Or Medicinal Preparations HETEROCYCLIC COMPOUNDS Technologies For Adaptation To Climate Change Preparations For Medical; Dental Or Toiletry Purposes |
| Extended Family | 064-760-219-891-367 024-347-230-340-830 090-154-689-124-958 177-607-047-303-050 036-287-534-635-084 110-172-336-156-72X 127-720-138-606-349 060-214-495-943-692 100-369-824-495-591 078-855-983-114-299 135-057-245-019-010 000-763-895-313-134 045-752-354-757-970 012-153-799-724-336 145-874-146-057-591 |
| Patent ID | 20190367532 |
| Inventor/Author | Ritz Daniel Rueedi Georg Zumbrunn Cornelia |
| IPC | C07D498/04 A61P31/04 |
| Status | Inactive |
| Owner | Actelion Pharmaceuticals Ltd Idorsia Pharmaceuticals Ltd |
| Simple Family | 064-760-219-891-367 024-347-230-340-830 090-154-689-124-958 177-607-047-303-050 036-287-534-635-084 110-172-336-156-72X 127-720-138-606-349 060-214-495-943-692 100-369-824-495-591 078-855-983-114-299 135-057-245-019-010 000-763-895-313-134 045-752-354-757-970 012-153-799-724-336 145-874-146-057-591 |
| CPC (with Group) | A61P31/04 C07D498/04 C07D519/00 Y02A50/30 A61K31/437 A61K31/5365 |
| Issuing Authority | United States Patent and Trademark Office (USPTO) |
| Kind | Patent Application Publication |
